Form 4: Veracyte Director Robert S. Epstein Granted Restricted Stock Units

Veracyte, Inc. Director Robert S. Epstein was granted 9,321 restricted stock units on June 18, 2025, increasing his beneficial ownership to 73,919 shares.

Summary

• Robert S. Epstein, a Director of Veracyte, Inc. (VCYT), was granted 9,321 shares of Common Stock in the form of restricted stock units.
• The transaction occurred on June 18, 2025, with an acquisition price of $0, indicating a grant rather than a purchase.
• Following this transaction, Mr. Epstein's beneficial ownership of Veracyte Common Stock increased to 73,919 shares.
• The restricted stock units are scheduled to vest in full on the first anniversary of the grant date (June 18, 2026) or immediately prior to the Company's next annual meeting of stockholders, if earlier.
• Additionally, the restricted stock units will vest in full in the event of a change in control of Veracyte.

Sentiment

Score: 7

Explanation: The grant of restricted stock units to a director is generally a positive signal, indicating alignment of interests and commitment, though it's a routine compensation event rather than a major strategic announcement.

Positives

• The grant of restricted stock units to a director aligns the director's interests with long-term shareholder value.
• Increased beneficial ownership by a director demonstrates continued commitment to the company.

Future Outlook

The vesting schedule for the granted restricted stock units indicates future equity ownership for the director, aligning long-term incentives with company performance.

Industry Context

This Form 4 filing reflects a routine equity compensation event for a director in the biotechnology/diagnostics industry, a common practice to incentivize leadership and align their interests with shareholder value. Such grants are standard across publicly traded companies, including those in the healthcare and life sciences sectors like Veracyte.

Comparison to Industry Standards

• The grant of restricted stock units to a director is a standard form of equity compensation in the U.S. public company landscape, particularly within the biotechnology and diagnostics sectors.
• Companies like Exact Sciences Corp. (EXAS) or Guardant Health, Inc. (GH) also utilize similar equity-based incentives for their directors and executives to foster long-term commitment and performance alignment.
• The vesting schedule, tied to a one-year anniversary or the next annual meeting, is also a common structure for director RSU grants, reflecting typical board service terms.

Stakeholder Impact

• Shareholders: The grant of restricted stock units to a director aligns the director's long-term interests with shareholder value, as the value of the units is tied to the company's stock performance.

Next Steps

• Vesting of the 9,321 restricted stock units on June 18, 2026, or earlier upon the Company's next annual meeting of stockholders or a change in control.

Key Dates

Recommendation

Keywords

Veracyte, VCYT, Form 4, SEC filing, insider transaction, restricted stock units, RSU, director compensation, equity grant, beneficial ownership